抗体介导肝靶向抗肿瘤给药系统的研究进展(3)
[ 7 ] ZHANG YF，HO M. Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma[J]. Sci Rep，2016.DOI：10.1038/srep33878.
[ 8 ] 刘燕丽，宦怡，魏光全，等. Hab18-SPIO磁共振造影剂的制备及其实验研究[J].实用放射学杂志，2006，22(4)：385-389.
[ 9 ] YIN XB，WU LQ，HUANG MW，et al. Humanized anti- VEGFR-2 ScFv-As2O3-stealth nanoparticles，an antibody conjugate with potent and selective anti-hepatocellular carcinoma activity[J]. Biomed Pharmacother，2014，68(5)：597-602.
, http://www.100md.com
[10] KIM H，HONG SH，KIM JY，et al. Preclinical development of a humanized neutralizing antibody targeting HGF[J]. Exp Mol Med，2017，49(3)：e309.
[11] AHN HM，RYU J，SONG JM，et al. Anti-cancer activity of novel TM4SF5-tarteting antibodies through TM4SF5 neutralization and immune cell-mediated cytotoxicity[J]. Theranostics，2017，7(3)：594-613.
[12] CHENG WWK，DAS D，SURESH M，et al. Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells[J]. Biochim Biophys Acta，2007，1768(1)：21-29.
, 百拇医药
[13] SCOTT AM，WOLCHOK JD，OLD LJ. Antibody therapy of cancer[J]. Nat Rev Cancer，2012，12(4)：278-287.
[14] SAPRA P，TYAGI P，ALLEN TM. Ligand-targeted liposomes for cancer treatment[J]. Curr Drug Deliv，2005，2(4)：369-381.
[15] HOSSEINI M，HAJI-FATAHALIHA M，JADIDI-NIARA- GH F，et al. The use of nanoparticles as a promising theraprutic approach in cancer immunotherapy[J]. Artif Cell Nanomed Biotechnol，2016，44(4)：1051-1061.
, 百拇医药
[16] WANG AZ，GU F，ZHANG L，et al. Biofunctionalized targeted nanoparticles for therapeutic applications[J]. Expert Opin Biol Ther，2008，8(8)：1063-1070.
[17] 管庆霞，华晓丹，李伟男，等.载中药肝靶向纳米给药系统的研究进展[J].中国药房，2015，26(7)：1002-1005.
[18] QIN JM，YIN PH，LI Q，et al. Anti-tumor effects of brucine immuno-nanoparticles on hepatocellular carcinoma[J]. Inter J Nanomed，2012，7(8)：369-379.
[19] ZHU R，ZHANG CG，LIU Y，et al. CD147 monoclonal antibody mediated by chitosan nanoparticles loaded with α-hederin enhances antineoplastic activity and cellular uptake in liver cancer cells[J]. Sci Rep，2015.DOI：10.1038/srep17904.
, 百拇医药
[20] YANG J，HUANG X，LUO F，et al. Preparation and functional studies of hydroxyethyl chitosan nanoparticles loaded with anti-human death receptor 5 single-chain antibody[J]. Onco Targets Ther，2014，7(9)：779-787.
[21] 季可非，劉宏，郭敏.甲氨蝶呤给药系统的研究进展[J]. 中国药房，2016，27(25)：3586-3588.
[22] 沈俊俊，姚登福.单克隆抗体介导的肝癌靶向治疗[J].国际内科学杂志，2009，36(1)：49-53.
[23] HU H，CHEN D，LIU Y，et al. Preparation and targeted delivery of immunoliposomes bearing poly(ethylene glycol)-coupled humanized anti-hepatoma disulfide-stabilized Fv (hdsFv25) in vitro[J]. Pharmazie，2006，61(8)：685-688., http://www.100md.com(王丹丹 朱静 张玮 吴卫)
[ 8 ] 刘燕丽，宦怡，魏光全，等. Hab18-SPIO磁共振造影剂的制备及其实验研究[J].实用放射学杂志，2006，22(4)：385-389.
[ 9 ] YIN XB，WU LQ，HUANG MW，et al. Humanized anti- VEGFR-2 ScFv-As2O3-stealth nanoparticles，an antibody conjugate with potent and selective anti-hepatocellular carcinoma activity[J]. Biomed Pharmacother，2014，68(5)：597-602.
, http://www.100md.com
[10] KIM H，HONG SH，KIM JY，et al. Preclinical development of a humanized neutralizing antibody targeting HGF[J]. Exp Mol Med，2017，49(3)：e309.
[11] AHN HM，RYU J，SONG JM，et al. Anti-cancer activity of novel TM4SF5-tarteting antibodies through TM4SF5 neutralization and immune cell-mediated cytotoxicity[J]. Theranostics，2017，7(3)：594-613.
[12] CHENG WWK，DAS D，SURESH M，et al. Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells[J]. Biochim Biophys Acta，2007，1768(1)：21-29.
, 百拇医药
[13] SCOTT AM，WOLCHOK JD，OLD LJ. Antibody therapy of cancer[J]. Nat Rev Cancer，2012，12(4)：278-287.
[14] SAPRA P，TYAGI P，ALLEN TM. Ligand-targeted liposomes for cancer treatment[J]. Curr Drug Deliv，2005，2(4)：369-381.
[15] HOSSEINI M，HAJI-FATAHALIHA M，JADIDI-NIARA- GH F，et al. The use of nanoparticles as a promising theraprutic approach in cancer immunotherapy[J]. Artif Cell Nanomed Biotechnol，2016，44(4)：1051-1061.
, 百拇医药
[16] WANG AZ，GU F，ZHANG L，et al. Biofunctionalized targeted nanoparticles for therapeutic applications[J]. Expert Opin Biol Ther，2008，8(8)：1063-1070.
[17] 管庆霞，华晓丹，李伟男，等.载中药肝靶向纳米给药系统的研究进展[J].中国药房，2015，26(7)：1002-1005.
[18] QIN JM，YIN PH，LI Q，et al. Anti-tumor effects of brucine immuno-nanoparticles on hepatocellular carcinoma[J]. Inter J Nanomed，2012，7(8)：369-379.
[19] ZHU R，ZHANG CG，LIU Y，et al. CD147 monoclonal antibody mediated by chitosan nanoparticles loaded with α-hederin enhances antineoplastic activity and cellular uptake in liver cancer cells[J]. Sci Rep，2015.DOI：10.1038/srep17904.
, 百拇医药
[20] YANG J，HUANG X，LUO F，et al. Preparation and functional studies of hydroxyethyl chitosan nanoparticles loaded with anti-human death receptor 5 single-chain antibody[J]. Onco Targets Ther，2014，7(9)：779-787.
[21] 季可非，劉宏，郭敏.甲氨蝶呤给药系统的研究进展[J]. 中国药房，2016，27(25)：3586-3588.
[22] 沈俊俊，姚登福.单克隆抗体介导的肝癌靶向治疗[J].国际内科学杂志，2009，36(1)：49-53.
[23] HU H，CHEN D，LIU Y，et al. Preparation and targeted delivery of immunoliposomes bearing poly(ethylene glycol)-coupled humanized anti-hepatoma disulfide-stabilized Fv (hdsFv25) in vitro[J]. Pharmazie，2006，61(8)：685-688., http://www.100md.com(王丹丹 朱静 张玮 吴卫)